Product Theater – TREMFYA® (guselkumab): A First-line Biologic with Clinical Data vs Adalimumab and Secukinumab

Featuring Guest Faculty, Jeffrey Johnson, PA-C For Friday afternoon’s product theater, Jeffrey Johnson, PA-C , discussed psoriasis and treatment with Tremfya. Mr. Johnson reminded the audience psoriasis is not just an inflammatory skin disease but a global inflammatory disease which can affect all organ systems. For example, patients with moderate to severe psoriasis are 54% …